Table 2.

Pharmacokinetic variables of erlotinib after p.o. and i.p. administration in WT and Bcrp1/Mdr1a/1b−/− mice

WTBcrp1/Mdr1a/1b−/−P
AUC p.o. (ng*h/mL)*4,957 ± 1,7357,419 ± 1,7200.01
AUC i.p. (ng*h/mL)11,873 ± 2,77912,054 ± 1,896>0.2 (NS)
Oral bioavailability (%; 95% confidence interval)40.0 (27.8-57.7)60.4 (48.6-75.1)0.02
  • NOTE: Mean ± SE.

  • * AUC up to infinity after oral administration of erlotinib hydrochloride.

  • AUC up to infinity after i.p. administration of erlotinib hydrochloride.